Oncotarget

Research Papers:

Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease

Hua Bai, Shuang Wu, Rong Wang, Ji Xu and Lijuan Chen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:85392-85400. https://doi.org/10.18632/oncotarget.19907

Metrics: PDF 1111 views  |   HTML 1986 views  |   ?  


Abstract

Hua Bai1,*, Shuang Wu1,*, Rong Wang1, Ji Xu1 and Lijuan Chen1

1Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

*These authors have contributed equally to this work

Correspondence to:

Lijuan Chen, email: chenljb@126.com

Keywords: multiple myeloma, T-help cells, interferon regulator factor 4, interleukin-17

Received: March 29, 2017     Accepted: July 12, 2017     Published: August 03, 2017

ABSTRACT

Interferon regulator factor 4 (IRF4) is characterized to be a member of interferon regulatory family, which is predominantly expressed in bone marrow plasma cells of patients with multiple myeloma (MM). Recent studies indicated IRF4 is critical for T-help cells (Th17) differentiation and interleukin-17 (IL-17) secretion. Here, a total of 58 MM patients were enrolled in this study, the proportions of Th17 cells and T regulatory (Treg) cells in peripheral blood mononuclear cells (PBMCs) were determined by flow cytometric analysis. Immunohistochemistry was employed to detect the IRF4 expression in bone marrow. Herein, we observed a significant increase of IRF4 in bone marrow accompanied with a notable up-regulation of Th17 cells in PBMC within MM patients compared with healthy donors. Furthermore, the proportions of Th17 cells and serum IL-17 levels were higher in patients with stage III than stage I & II MM patients, and those parameters were positively correlated with the expression of IRF4 in these cases. These results for the first time indicate that a crosstalk between IRF4 and Th17 cells is associated with MM prognosis, and IRF4 may be served an important target for MM immunotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19907